ArticleKidney international reports2026
Association of Metabolic Dysfunction-Associated Steatotic Liver Disease and Kidney Failure in the CKD Population.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Although fatty liver disease is a known risk factor for chronic kidney disease (CKD), its association with kidney failure remains unclear, especially after its redefinition as metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to quantify the association between MASLD and kidney failure in the CKD population by generating epidemiological data. Methods: We used 187,881 individuals with CKD from medical screening data of the National Health Insurance Service (NHIS) database of Korea. The population was categorized with no steatotic liver disease, MASLD, MASLD with increased alcohol intake, and alcoholic liver disease or steatotic liver disease with other specific etiologies. The risk of kidney failure was analyzed using Cox proportional hazard models adjusting demographic and clinical variables. Results: The study population had mean age of 63.3 years with 58% females. During the median of 9.28 (9.03-9.63) years of follow-up, 7497 (4%) events of kidney failure were identified. In the adjusted model, the "MASLD" group showed higher risk of kidney failure (hazard ratio [HR]: 1.146 [1.078- 1.219]) compared with "no steatotic liver disease." However, "MASLD with increased alcohol intake" ([HR 0.981 [0.834-1.154]) or "alcoholic liver disease or steatotic liver disease with other specific etiologies" (HR 1.098, [0.991-1.216]) showed nonsignificant difference. The association between MASLD and kidney failure was particularly accentuated in females (HR 1.301 [(1.192-1.420]), old age, nonhypertension, nonalbuminuria, and nonsmoking subgroup. Conclusion: In this large-scale observational study, MASLD was associated with kidney failure in individuals with CKD. Our findings highlight the importance of risk stratification in certain patients to prevent kidney failure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.